SCHEMBL23924487

SCHEMBL23924487

CCOC[C@@H](n1cnc2cnc3ccccc3c21)C(O)(CC)CC

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP5 P45974 1/20 0.34
MYC P01106 1/20 0.34
TLR7 Q9NYK1 6/20 0.34
TLR8 Q9NR97 2/20 0.34
NUDT1 P36639 1/20 0.34
TSHR P16473 1/20 0.33
RAB9A P51151 3/20 0.32
NPC1 O15118 1/20 0.32
MPO P05164 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
RECQL P46063 1/20 0.31
MAPK10 P53779 1/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
ALDH1A1 P00352 1/20 0.31
ATM Q13315 1/20 0.30
PKM P14618 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23924488 1.00 USP5 (0.34) USP5MYCTLR7TLR8NUDT1
SCHEMBL21994853 0.90 TLR7 (0.36) USP5MYCTLR7TLR8NUDT1
SCHEMBL21995110 0.90 TLR7 (0.36) USP5MYCTLR7TLR8NUDT1
SCHEMBL23924725 0.87 TLR7 (0.34) USP5MYCTLR7TLR8NUDT1
SCHEMBL23924727 0.87 TLR7 (0.34) USP5MYCTLR7TLR8NUDT1
SCHEMBL21995048 0.82 MYC (0.37) USP5MYCTLR7TLR8NUDT1
SCHEMBL22749237 0.81 USP5 (0.41) USP5TLR7NUDT1TSHRMPO
SCHEMBL29508378 0.81 USP5 (0.41) USP5TLR7NUDT1TSHRMPO
SCHEMBL22043258 0.81 TLR7 (0.52) TLR7TLR8NUDT1LMNA
SCHEMBL22043259 0.81 TLR7 (0.52) TLR7TLR8NUDT1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540137-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2026-02-03 US disclosed
US-20240300947-A1 N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-09-12 US disclosed
US-12024514-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-07-02 US disclosed
CN-113166143-B N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions and methods 舒万诺知识产权公司 2024-06-04 CN disclosed
EP-3887369-B1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2024-05-08 EP disclosed
US-20210323962-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2021-10-21 US disclosed
CN-113166143-A N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods 3M创新有限公司 2021-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12540137-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IRF3, IFNAR1, IFNG USP5 3940/4885MYC 2013/4885TLR7 51/4885
US-20240300947-A1 N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods IFNG, IFNAR1, IRF3 USP5 3632/4885MYC 284/4885TLR7 20/4885
US-20210323962-A1 N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS IFNG, IFNAR1, IRF3 USP5 3406/4885MYC 299/4885TLR7 17/4885
US-12024514-B2 N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods IFNG, IFNAR1, IRF3 USP5 3406/4885MYC 299/4885TLR7 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.